pexels-karolina-grabowska-4021779.jpg

Targeting Deadly Brain Cancer
Using Remote-Controlled Nanotechnology


We hold numerous patents and licenses to innovative technology, including nanoparticle scintillators, which can target and destroy with timed precision.

A message from our founder, John Clark

Global Cancer Technology (GCT) is an emerging biopharmaceutical company headquartered in San Diego, CA.

header-2.png

Cutting Edge Technology

Nanoparticle technology enables us to attack disease with timed precision.

Dr. Ekokobe Fonkem.jpg

Dr. Ekokobe Fonkem, director of neuro-oncology and an associate professor and chair in the Department of Neurology at Barrow Neurological Institute.

It takes a team effort

In collaboration with world renowned researchers and institutions, including the Barrow Neurological Institute, the University of San Diego and more, we are developing innovative treatments to fight deadly diseases like COVID and cancer.

 

“Incurable diseases like glioblastoma, commonly called ‘brain cancer,’ impose a high degree of suffering in patients who have few to no options regarding treatment. Being part of a collaborative effort around the creative application of new technologies gives us hope for a better future for these patients.”

Surgeons in Operating Room

Cancer Treatment

Global Cancer Technology has numerous patents and other IP that might lead to breakthroughs in cancer therapy. The company is partnering with highly acclaimed academic institutions such as UCSD and the Barrow Neurological Institute, along with industry leaders, to make these therapies available to patients as quickly as possible. Global Cancer Technology’s lead cancer technology is its remote-controlled cancer drug delivery platform.

Learn more about Global Cancer Technology's remote-controlled cancer drug delivery platform by clicking here.

Scientist Using Microscope

COVID-19 Nanoparticle Treatment

​The coronavirus is mutating uncharacteristically fast. New strains are 50-70% more transmissible. The "UK Variant" [B.1.1.7] is now in 45 countries. Two other variants, the "South Africa Variant" [B.1.351] and one recently identified in Brazil could render existing treatments ineffective. Scott Gottlieb, the former director of the FDA, stated: “The South Africa variant is very concerning right now because it does appear that it may obviate some of our medical countermeasures, particularly the antibody drugs.

​

GCT has developed a method that targets coronavirus with high specificity and binds irreversibly to the virus particles. Once bound, an ultra-low dose x-ray (about 400 times less than a typical chest x-ray) activates the nanoparticles bound to the virus. Activation causes a blast of ultra-violet to be emitted directly into the coronavirus which kills it with timed precision.

Learn more about Global Cancer Technology's COVID-19 nanoparticle treatment by clicking here.

pexels-artem-podrez-5726794.jpg

Help us develop these life-saving technologies.
Invest now.

$500

Minimum Investment

$2.00

Share Price

Invest in Global Cancer Technology
Download Investor Report

View offering circular

*Investments in early-stage biopharmaceutical companies carries risk and returns are not guaranteed. Contact us for Preferred Pricing for investments of $10,000 or more.

 

Need more info before becoming an investor?

Following the close of an investment round last year at $1 per share, Global Cancer Technology opened a new investment round at $2 per share. This is your opportunity to own shares in an emerging medical technology company that is developing a patented nanotechnology treatment for both COVID-19 and cancer.

Subscribe to get notified of our progress.

Thanks for submitting!

  • Facebook
  • LinkedIn
  • YouTube

THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK. THIS INVESTMENT IS SUITABLE ONLY FOR PERSONS WHO CAN BEAR THE ECONOMIC RISK FOR AN INDEFINITE PERIOD OF TIME AND WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. FURTHERMORE, INVESTORS MUST UNDERSTAND THAT SUCH INVESTMENT IS ILLIQUID AND IS EXPECTED TO CONTINUE TO BE ILLIQUID FOR AN INDEFINITE PERIOD OF TIME. NO PUBLIC MARKET EXISTS FOR THE SECURITIES, AND NO PUBLIC MARKET MAY DEVELOP FOLLOWING THIS OFFERING.

 

THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES OR BLUE SKY LAWS AND ARE BEING OFFERED AND SOLD IN RELIANCE ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND STATE SECURITIES OR BLUE SKY LAWS. ALTHOUGH AN OFFERING STATEMENT HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION (THE “SEC”), THAT OFFERING STATEMENT DOES NOT INCLUDE THE SAME INFORMATION THAT WOULD BE INCLUDED IN A REGISTRATION STATEMENT UNDER THE SECURITIES ACT. THE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SEC, ANY STATE SECURITIES COMMISSION OR OTHER REGULATORY AUTHORITY, NOR HAVE ANY OF THE FOREGOING AUTHORITIES PASSED UPON THE MERITS OF THIS OFFERING OR THE ADEQUACY OR ACCURACY OF THE SUBSCRIPTION AGREEMENT OR ANY OTHER MATERIALS OR INFORMATION MADE AVAILABLE TO SUBSCRIBERS IN CONNECTION WITH THIS OFFERING.

 

SUBSCRIBERS WHO ARE NOT “ACCREDITED INVESTORS” (AS THAT TERM IS DEFINED IN SECTION 501 OF REGULATION D PROMULGATED UNDER THE ACT) ARE SUBJECT TO LIMITATIONS ON THE AMOUNT THEY MAY INVEST, AS SET OUT IN SECTION 4. THE COMPANY IS RELYING ON THE REPRESENTATIONS AND WARRANTIES SET FORTH BY EACH SUBSCRIBER IN THIS SUBSCRIPTION AGREEMENT AND THE OTHER INFORMATION PROVIDED BY SUBSCRIBER IN CONNECTION WITH THIS OFFERING TO DETERMINE THE APPLICABILITY TO THIS OFFERING OF EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE ACT.

 

THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.

 

THE COMPANY MAY NOT BE OFFERING THE SECURITIES IN EVERY STATE. THE OFFERING MATERIALS DO NOT CONSTITUTE AN OFFER OR SOLICITATION IN ANY STATE OR JURISDICTION IN WHICH THE SECURITIES ARE NOT BEING OFFERED.

 

THE COMPANY RESERVES THE RIGHT IN ITS SOLE DISCRETION AND FOR ANY REASON WHATSOEVER TO MODIFY, AMEND AND/OR WITHDRAW ALL OR A PORTION OF THE OFFERING AND/OR ACCEPT OR REJECT IN WHOLE OR IN PART ANY PROSPECTIVE INVESTMENT IN THE SECURITIES OR TO ALLOT TO ANY PROSPECTIVE INVESTOR LESS THAN THE AMOUNT OF SECURITIES SUCH INVESTOR DESIRES TO PURCHASE. EXCEPT AS OTHERWISE INDICATED, THE OFFERING MATERIALS SPEAK AS OF THEIR DATE. NEITHER THE DELIVERY NOR THE PURCHASE OF THE SECURITIES SHALL, UNDER ANY CIRCUMSTANCES, CREATE ANY IMPLICATION THAT THERE HAS BEEN NO CHANGE IN THE AFFAIRS OF THE COMPANY SINCE THAT DATE.

© 2021 by Global Cancer Technology